Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

50.200
+4.60010.09%
Volume:13.48M
Turnover:655.49M
Market Cap:333.18B
PE:36.43
High:50.400
Open:46.080
Low:45.380
Close:45.600
52wk High:94.869
52wk Low:43.020
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:5.00
T/O Rate:5.22%
Dividend:0.23
Dividend Rate:0.47%
EPS(LYR):1.378
ROE:12.46%
ROA:7.02%
PB:4.43
PE(LYR):36.43
PS:9.11

Loading ...

HENGRUI PHARMA's HRG2010 Capsule Marketing Application Accepted by NMPA

Stock News
·
Aug 24

Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$82.18 From HK$87.49, Keeps at Buy

MT Newswires Live
·
Aug 24

Hengrui Pharma's Half-Year Report: Heavy Spending Fails to Drive Growth as Former Sector Leader Struggles with Revenue Without Profit Expansion

Deep News
·
Aug 24

Movement Alert|HENGRUI PHARMA Falls 3.03% in Regular Trading, BOCOM International Cuts Target Price Citing Continued Pressure on Legacy Products

Market Focus
·
Aug 24

Hengrui Pharma's Growth Architecture Shifts: Second Growth Engine Accelerates as Global Valuation Framework Expands

Stock News
·
Aug 23

Hengrui Pharma Gets Nod to Trial SHR-8203 Injection

MT Newswires Live
·
Aug 21

Hengrui Pharma Unit Gets China Nod for Lupus Drug Trial

MT Newswires Live
·
Aug 21

Movement Alert|HENGRUI PHARMA Declines 3.18% in Regular Trading, Extending Sell-Off on Weak H1 Earnings Quality

Market Focus
·
Aug 21

Hengrui Pharmaceuticals Unit Gets China Marketing Nod for Paroxysmal Nocturnal Hemoglobinuria Drug

MT Newswires Live
·
Aug 20

Jiangsu Hengrui Pharmaceuticals- Nmpa Notice Approving Developed Class 1 Innovative Drug Licancopan Fumarate (Hrs-5965) Capsules for Marketing

THOMSON REUTERS
·
Aug 20

HENGRUI PHARMA (01276) Gets Clinical Trial Approval for SHR-7012 Injection Targeting Cutaneous Lupus Erythematosus

Stock News
·
Aug 20

Jiangsu Hengrui Hong Kong Shares Hit Record Low on Quarterly Profit Miss

Reuters
·
Aug 20

Movement Alert|HENGRUI PHARMA Falls 8.55% in Regular Trading, H1 Revenue Declines as Core Profit Drops 12.7%

Market Focus
·
Aug 20

Hengrui Pharma Announces Resignation of Joint Company Secretary Liu Xiaohan

Bulletin Express
·
Aug 19

Hengrui Pharma Appoints Tian Fei as New Board Secretary

Stock News
·
Aug 19

HENGRUI PHARMA Proposes New H-Share Incentive Scheme for 2026

Stock News
·
Aug 19

Hengrui Pharma Maintains H1 2026 Profitability; Innovative Drug Sales Rise 16.4% Despite Flat Revenue

Bulletin Express
·
Aug 19

Hengrui Pharma Unveils 2026 A-Share Employee Stock Ownership Plan Valued at Approx. RMB 0.34 Billion

Bulletin Express
·
Aug 19

Hengrui Pharma's First-Half Results Unveil Strategic Shifts: From Innovative Drugs to NewCo Expansion

Stock News
·
Aug 19

HENGRUI PHARMA: Wellington Management Group LLP Disposes of Shares, Long Position Falls to 5.94%

HK Disclosure
·
Aug 19